Dermatology
| Psoriasis
Dermatology
Psoriasis
Roflumilast foam 0.3% in patients with scalp and body psoriasis in the phase 3 ARRECTOR trial: Efficacy, patient-reported outcomes, and safety
book_2
Source:
EADV Congress 2023 - Oral session
calendar_today
Published on Medfyle:
October 2023
import_contacts
6
min
In this medfyle
Despite the advent of systemic treatments, there remains a need for topicals in psoriasis. Foam is easier to apply than traditionally greasy formulations. Here, we describe results from the Phase 3 ARRECTOR trial in patients aged 12 and older.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the EADV Congress 2023. The content is developed by Infomedica in collaboration with the EADV.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content. The viewpoints expressed may not represent Infomedica, or the EADV.
©2023 Infomedica. All rights reserved.
